Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...

On Thursday, Reuters reported weak U.S. prescription data is contributing to investor concerns that Novo Nordisk is no longer ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...